Abstract

BackgroundColorectal cancer (CRC) is one of the most frequently diagnosed cancers worldwide and thus mouse models of CRC are of significant value to study the pathogenesis. The Azoxymethane/Dextran sulfate sodium (AOM/DSS) model is a widely used, robust initiation-promotion model for chemical induction of colitis-associated CRC in rodents. However, the dosage of chemicals, treatment regimens and outcome measures vary greatly among studies employing this model. Thus, the aim of this study was to examine an AOM/DSS model involving a reduced (1%) dose of DSS for induction of carcinogenesis in A/J and C57BL/6J (B6) mice.ResultsWe show that colonic preneoplastic lesions can be reliably detected in A/J and B6 mice by use of a AOM/DSS model involving a single injection of 10 mg/kg AOM followed by three 7-day cycles of a low-dose (1%) DSS administration. Supporting existing evidence of A/J mice exhibiting higher susceptibility to AOM than B6 mice, our AOM/DSS-treated A/J mice developed the highest number of large colonic lesions. Clinical symptoms in both strains subjected to the AOM/DSS treatment did not persist in-between treatment cycles, demonstrating that the animals tolerated the treatment well.ConclusionsOur findings suggest that a reduced dose of DSS in the AOM/DSS model can be considered in future studies of early phase colorectal carcinogenesis in the A/J and B6 mouse strains using preneoplastic lesions as an outcome measure, and that such regimen may reduce the risk of early trial terminations to accommodate human endpoints. Overall, our data emphasize the importance of devoting attention towards choice of protocol, outcome measures and mouse strain in studies of CRC in mice according to the study purpose.

Highlights

  • Colorectal cancer (CRC) is one of the most frequently diagnosed cancers worldwide and mouse models of CRC are of significant value to study the pathogenesis

  • We evaluated an AOM/dextran sulfate sodium (DSS) model involving a single injection of AOM in combination with three treatment cycles of a reduced (1%) dose of DSS for induction of carcinogenesis in colons of A/J and B6 mice, reportedly representing two extremes with respect to AOM susceptibility

  • Pairwise comparisons showed a significantly lower bodyweight in the Azoxymethane/Dextran sulfate sodium (AOM/DSS)–treated A/J mice compared to the AOM/DSS–treated B6 mice at day 56 (p = 0.048) and 60 (p = 0.050), and a significantly lower bodyweight in the AOM/DSS–treated B6 compared to the control B6 group at day 60 (p = 0.031) and 62 (p = 0.010)

Read more

Summary

Introduction

Colorectal cancer (CRC) is one of the most frequently diagnosed cancers worldwide and mouse models of CRC are of significant value to study the pathogenesis. The Azoxymethane/Dextran sulfate sodium (AOM/DSS) model is a widely used, robust initiation-promotion model for chemical induction of colitis-associated CRC in rodents. Experimental mouse models that mimic the initiation and progression of CRC is of great importance to study causes, mechanisms and preventive agents Genetic models such as the Min (multiple intestinal neoplasia) mice harboring a mutant allele of the murine Apc (adenomatous polyposis coli) gene are widely used [14]. Another approach is via chemical induction, such as administration of the specific colorectal pro-carcinogen azoxymethane (AOM) [14]. The AOM/DSS model is considered robust and reproducible, and it has emerged to become one of the most frequently used models to study inflammation-associated colorectal carcinogenesis in rodents [14, 21,22,23]

Objectives
Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.